Table 6_Evaluating the in vivo effects of Aspirin on vaginal inflammation and barrier function.xls

In this study, we evaluated the in vivo potential of the anti-inflammatory drug Acetylsalicylic Acid (ASA) to lower proinflammatory cytokine production, restore vaginal barrier integrity and reduce the frequency of activated T cells that serve as targets for HIV infection.

Daily intraperitoneal administration of ASA in mice had no effect on epithelial layer structure and CD4⁺ T cell activation status at homeostasis but significantly reduced barrier disruption in response to inflammatory bacteria Mobiluncus mulieris (M. muleiris). ASA treatment lowered the frequency of activated CXCR6⁺ T_H17 subsets in the vaginal mucosa in response to M. muleiris and Gardnerella vaginalis challenge, also reducing the number of CCR5⁺ T cells in the latter.